Glenmark Pharmaceuticals Settles Generic Drug Price-Fixing Claims for $29.6 Million

A coalition of 48 states and territories, including Nebraska, South Carolina, and Nevada, secured a $29.6 million settlement from Glenmark Pharmaceuticals to resolve allegations of price manipulation. The drugmaker is accused of conspiring to artificially inflate prices for more than 100 generic prescription drugs—including medications for cancer, diabetes, and asthma—between May 2009 and December 2019. Prosecutors allege industry executives used phone calls, texts, and casual outings to restrain trade and reduce competition.

Under the agreement, Glenmark must implement internal antitrust reforms and cooperate in ongoing litigation against 33 other corporate defendants and 25 individual executives. Nevada will allocate approximately $41,000 to state agencies and over $13 million to a consumer restitution fund. Nebraska and South Carolina are set to receive $128,000 and $118,890, respectively. Consumers who purchased the affected generics during the ten-year window may be eligible for compensation.

This settlement follows previous agreements with Heritage, Apotex, Bausch, and Lannett totaling $66.95 million, bringing the total recovery in these efforts to over $96 million. Broader litigation involving Teva Pharmaceuticals and other manufacturers continues, with the first trial expected to begin in late 2026 in Hartford, Connecticut.